ReviewFrontiers in pharmacology2024
Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Isoniazid impairs memory function in male Swiss mice by elevating pro-inflammatory cytokines and disruption of hippocampal, and prefrontal cortex neuronal morphology.Metabolic brain disease · 2026Article
- Design, Synthesis, Antimycobacterial Evaluation, and In Silico Investigation of Benzisothiazole-Based Hydrazide Derivatives as Potential Anti-Tuberculosis Agents.Chemical biology & drug design · 2026Article
- Pharmacogenomics and Epigenetic Regulation Transforming Pediatric Precision Therapeutics.Journal of personalized medicine · 2026Review
- Rapid Eukaryotic Impedimetric Biosensing of Naproxen and Isoniazid: A Proof-of-Concept for Acute Toxicity Monitoring.Biosensors · 2026Article
- Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.EMBO molecular medicine · 2026Review
- Synthesis, SAR, and multi-target evaluation of isonicotinoyl hydrazones as potent MPO/AChE inhibitors and metal chelators for Alzheimer's disease.Scientific reports · 2026Article
- Isoniazid subverting erythrocyte homeostasis: implications for tuberculosis therapy.Frontiers in pharmacology · 2026Article
- Review
- First episode of psychosis in a patient undergoing tuberculosis treatment.Breathe (Sheffield, England) · 2025Article
- Carbamate Prodrugs RestrictACS central science · 2025Article
- Tuberculous Meningitis in a One-Year-Old Child With Isoniazid-Induced Hepatotoxicity: A Case Report.Cureus · 2025Article
- Exploration of pyrazole-based pyridine-4-carbohydrazide derivatives as drug-resistantFuture medicinal chemistry · 2025Article
- Nutritional Deficiencies and Management in Tuberculosis: Pharmacotherapeutic and Clinical Implications.Nutrients · 2025Review
- How could emerging nanomedicine-based tuberculosis treatments outperform conventional approaches?Nanomedicine (London, England) · 2025Article
- Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024.Frontiers in pharmacology · 2025Article
- Exploring the Antimycobacterial Potential of Podocarpusflavone A fromPharmaceuticals (Basel, Switzerland) · 2024Article
- The role of isoniazid dosage and NAT2 gene polymorphism in the treatment of tuberculous meningitis.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the extraordinary anti-tubercular activity of isoniazid (INH), the drug-induced hepatotoxicity and peripheral neuropathy pose a significant challenge to its wider clinical use. The primary cause of INH-induced hepatotoxicity is
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.